reports
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...
- Wim Lewi
Xior Feed Back from the Xior Analyst call on FY26 guidance-Correction
The surprise call on the outlook update was only open to analysts and basically served to highlight the past 10 years of growth. Nevertheless €2.30 EPRA EPS, comes above consensus and our €2.25 estimate. Xior wants to show that after 2 years of transition and flat EPS, they will show growth again. Under COO, Kristina Olsen, Xior has also improved its internal operations and budget planning for next year had already finished. The focus is on internal efficiency gains and rental growth from realis...
- Carole Braudeau
- Carole Braudeau
- Aurelien Sivignon
- Yan Derocles
- ING Helpdesk
Benelux Morning Notes
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
- Aurelien Sivignon
- Yan Derocles
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Robert Jan Vos
- Usama Tariq
- Wim Lewi
Xior Xior rings the bell with a FY26 EPRA EPS outlook of €2.30
Today Xior celebrates its 10 year listing on the Brussels stock exchange. At the same time it issued a FY26 EPRA EPS outlook and expects EPS growth of +4% in FY26 to €2.30 vs. FY25 of €2.21. Xior is confident about the future, driven by its student housing platform and 98% occupancy. It expects rental growth from additions to its scalable operations and structural market scarcity to drive rental increases. Also efficiency gains should add to profitability gains. Xior will focus on portfolio opti...
- Jacob Mekhael
- Mathijs Geerts Danau
Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...
Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...
- Wim Hoste
Ontex Profit warning, restructuring plan and new CEO appointment
Ontex just issued a profit warning revising its full-year outlook downwards. At the same time the board has decided to appoint Laurent Nielly , currently president of Ontex Europe, as the new CEO. The change will be effective as of May 2026 when the mandate of the current CEO comes to an end. The adjusted FY EBITDA25 guidance calls for a range of €175-€180m (previously €200-€210m) compared to KBC's forecast of €197m. Ontex's management is now accelerating an efficiency improvement initiative acr...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a g...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...
Laurent Nielly appointed as successor to CEO Gustavo Calvo Paz
Laurent Nielly appointed as successor to CEO Gustavo Calvo Paz Inside / regulated information Aalst, Belgium, December 11, 2025 – The Board of Directors of Ontex (Euronext: ONTEX) has decided to appoint Mr. Laurent Nielly as Chief Executive Officer, effective as from the end of Mr. Gustavo Calvo Paz’s mandate as Chief Executive Officer at Ontex’s next annual shareholders’ meeting, on May 5, 2026. Since 2021, Mr. Nielly has been President of Ontex’s Europe Division, leading our retailer brands and healthcare business across Europe. Prior to that, Mr. Nielly led Ontex’s business in Brazil....
Laurent Nielly benoemd tot opvolger van CEO Gustavo Calvo Paz
Laurent Nielly benoemd tot opvolger van CEO Gustavo Calvo Paz Voorkennis / gereglementeerde informatie Aalst, België, 11 december 2025 – De Raad van Bestuur van Ontex (Euronext: ONTEX) heeft besloten om de heer Laurent Nielly te benoemen tot Chief Executive Officer, met ingang vanaf het einde van het mandaat van de heer Gustavo Calvo Paz als Chief Executive Officer, dat afloopt op de volgende algemene aandeelhoudersvergadering van Ontex op 5 mei 2026. Sinds 2021 is de heer Nielly President van de Europese Divisie van Ontex, waar hij de leiding heeft over onze retailmerken en onze gezondhe...
Zealand Pharma and OTR Therapeutics enter multi-program strategic coll...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets...
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation ...
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity Louvain-la-Neuve, Belgium, December 11, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in China, to install a Rhodotron® in Jiaxing, Zhejiang Province, as a first step of the transition of China’s irradiation processing in...
China Gold Irradiation adopte la technologie d'irradiation par rayons...
China Gold Irradiation adopte la technologie d'irradiation par rayons X d'IBA afin d'accroître ses capacités de production Louvain-la-Neuve, Belgique, le 11 décembre 2025 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions d'irradiation industrielle par faisceau d'électrons et rayons X, annonce aujourd'hui avoir signé un contrat avec China Gold Irradiation (CGI), la plus grande société de services d'irradiation haut de gamme en Chine, pour l'installation d'un Rhodotron® à Jiaxing, dans la province du Zhejiang. Cet accord ré...
Following weakness in baby care consumer demand, Ontex revises full-ye...
Following weakness in baby care consumer demand, Ontex revises full-year outlook downward and accelerates a three-year efficiency improvement initiative Inside / regulated information Aalst, Belgium, December 11, 2025 – Ontex Group NV, a leading international developer and producer of personal care products, revises its full year expectations for revenue growth downward, following a of its baby care sales in October and November, as a result of weaker-than-expected consumer demand. This revision also impacts Ontex’s adjusted EBITDA, free cash flow and leverage ratio expectations. The cons...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.